Our Pipeline and Core (Nucleic Acid Modification) Technologies
-
Pipeline 1
- Target: Unmet early-stage bladder cancer (nonmuscle invasive bladder cancer, NMIBC)
- Number of eligible patients in Japan: About 10,000 per year
- Seed: Chemically modified microRNA-143 (patented)
- Mechanism: Mutant KRAS network suppressor molecular targeted drug
- Status: Non-clinical stage preparing for PI (Physician initiated clinical trials)
-
Pipeline 2
- Target: Unresectable mutant KRAS colorectal cancer
- Number of eligible patients in Japan: About 100,000 per year
- Seed: Chemically modified microRNA-143 (patented)
- Mechanism: Mutant KRAS network-suppressive molecularly targeted drug
- Status: Non-clinical stage
-
Core (nucleic acid modification) Technology 1: Ligand cross-linking technology to oligo-nucleic acids
- Ligand cross-linking for targeted delivery of nucleic acid (cross-linking at any location including 5' and 3' ends) .
- 15-minute cross-linking technique between nucleic acid and ligand
- Wide range of ligands can be selected by library construction such as sugar, peptide, protein, etc.
- Please ask us for more information.
-
Core (Nucleic Acid Modification) Technology 2: Dangling End Cross-linked Nucleic Acids
- Dangling Ends for Improved Nuclease Resistance
- Can modify various oligo-nucleic acids and nucleic acid molecules
- Please ask us for more information.
-
Our Modalities (Seeds) List
- Modality 1: Chemically modified microRNA-143
- Modality 2: Chemically modified microRNA-145
- Exploration of other modalities: Highly modified microRNA derivatives
- Target diseases: Solid tumors (melanoma), refractory cancers such as pancreatic cancer and breast cancer, blood cancers
- Discovery of microRNAs relevant to the treatment of neurological and cardiac diseases
- Prophylactic drug discovery: Search for microRNAs related to longevity of health
- Companion animal's drug development: Providing options in veterinary medicine where few therapies are available (e.g., canine oral cancer (melanoma))
